CA2878712A1 - Method for producing antibody molecules having inter-species, intra-target cross-reactivity - Google Patents

Method for producing antibody molecules having inter-species, intra-target cross-reactivity Download PDF

Info

Publication number
CA2878712A1
CA2878712A1 CA2878712A CA2878712A CA2878712A1 CA 2878712 A1 CA2878712 A1 CA 2878712A1 CA 2878712 A CA2878712 A CA 2878712A CA 2878712 A CA2878712 A CA 2878712A CA 2878712 A1 CA2878712 A1 CA 2878712A1
Authority
CA
Canada
Prior art keywords
species
antibody
human
reactivity
il22r
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2878712A
Other languages
English (en)
French (fr)
Inventor
Johannes Joseph Wilhelmus De Haard
Christophe Frederic Jerome Blanchetot
Sebastian Paul VAN DER WONING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ArgenX BVBA
Original Assignee
ArgenX SE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ArgenX SE filed Critical ArgenX SE
Publication of CA2878712A1 publication Critical patent/CA2878712A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2878712A 2012-08-31 2013-08-30 Method for producing antibody molecules having inter-species, intra-target cross-reactivity Abandoned CA2878712A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261695664P 2012-08-31 2012-08-31
US61/695,664 2012-08-31
PCT/EP2013/067979 WO2014033252A1 (en) 2012-08-31 2013-08-30 Method for producing antibody molecules having inter-species, intra-target cross-reactivity

Publications (1)

Publication Number Publication Date
CA2878712A1 true CA2878712A1 (en) 2014-03-06

Family

ID=49080903

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2878712A Abandoned CA2878712A1 (en) 2012-08-31 2013-08-30 Method for producing antibody molecules having inter-species, intra-target cross-reactivity

Country Status (10)

Country Link
US (1) US20150203840A1 (enExample)
EP (2) EP2977386A1 (enExample)
JP (1) JP6391574B2 (enExample)
CN (1) CN104583238A (enExample)
AU (2) AU2013310924B2 (enExample)
CA (1) CA2878712A1 (enExample)
DK (1) DK2890711T3 (enExample)
IL (1) IL236523B (enExample)
IN (1) IN2015DN00140A (enExample)
WO (1) WO2014033252A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2686347T3 (pl) 2011-03-16 2018-10-31 Argenx Bvba Przeciwciała przeciwko CD70
MX377091B (es) 2013-08-01 2025-03-07 Ludwig Inst For Cancer Res Ltd Proteina anti-garp y sus usos.
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
KR20190039937A (ko) 2016-07-08 2019-04-16 스태튼 바이오테크놀로지 비.브이. 항-ApoC3 항체 및 이의 사용 방법
GB201612337D0 (en) 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
CA3059133A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
GB201707561D0 (en) 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
US10538583B2 (en) 2017-10-31 2020-01-21 Staten Biotechnology B.V. Anti-APOC3 antibodies and compositions thereof
MA50516A (fr) 2017-10-31 2020-09-09 Staten Biotechnology B V Anticorps anti-apoc3 et leurs procédés d'utilisation
MX2020006213A (es) 2017-12-12 2020-09-14 Pionyr Immunotherapeutics Inc Anticuerpos anti-trem2 y metodos relacionados.
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
CA3090321A1 (en) 2018-02-05 2019-08-08 Stichting Vu Inverse agonistic anti-us28 antibodies
WO2020080941A1 (en) 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
WO2021241730A1 (ja) * 2020-05-29 2021-12-02 第一三共株式会社 炎症性腸疾患に対する治療用抗体
WO2022154664A1 (en) 2021-01-15 2022-07-21 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer
WO2024096735A1 (en) 2022-10-31 2024-05-10 Stichting Amsterdam UMC Single domain anti-cd169 antibodies
WO2024101989A1 (en) 2022-11-08 2024-05-16 Stichting Amsterdam UMC Activation inducible antigen receptors for adoptive immunotherapy
EP4631501A1 (en) 2024-04-09 2025-10-15 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Combinations of a calcium homeostasis disruptor with a death receptor 5 agonist for treating cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1034298E (pt) * 1997-12-05 2012-02-03 Scripps Research Inst Humanização de anticorpo murino
CN1735629B (zh) * 2002-11-08 2012-05-09 埃博灵克斯股份有限公司 针对肿瘤坏死因子-α的单结构域抗体及其用途
CA2505325C (en) * 2002-11-08 2014-02-25 Ablynx N.V. Stabilized single domain antibodies
MXPA05010136A (es) * 2003-03-24 2005-11-16 Zymogenetics Inc Anticuerpos anti-il-22ra, metodos y moleculas de enlace que se usan en la inflamacion.
CN1845937A (zh) * 2003-03-24 2006-10-11 津莫吉尼蒂克斯公司 抗il－20抗体和结合伴侣以及在炎症中的使用方法
EP2314623B1 (en) * 2005-06-21 2012-07-04 XOMA Technology Ltd. IL-1beta binding antibodies and fragments thereof
TWI417301B (zh) * 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
GB2461546B (en) * 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
CN107337734A (zh) * 2009-12-04 2017-11-10 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
GB201002238D0 (en) * 2010-02-10 2010-03-31 Affitech As Antibodies
PT2643019T (pt) * 2010-11-24 2019-04-23 Lexicon Pharmaceuticals Inc Anticorpos para notum pectinacetilesterase

Also Published As

Publication number Publication date
AU2017204188A1 (en) 2017-07-13
EP2890711A1 (en) 2015-07-08
AU2013310924A1 (en) 2015-01-29
US20150203840A1 (en) 2015-07-23
IL236523B (en) 2018-12-31
CN104583238A (zh) 2015-04-29
EP2890711B1 (en) 2017-01-04
AU2013310924A8 (en) 2015-04-30
AU2013310924B2 (en) 2017-08-03
EP2977386A1 (en) 2016-01-27
JP2015530087A (ja) 2015-10-15
DK2890711T3 (en) 2017-02-27
IL236523A0 (en) 2015-02-26
WO2014033252A1 (en) 2014-03-06
JP6391574B2 (ja) 2018-09-26
IN2015DN00140A (enExample) 2015-06-12

Similar Documents

Publication Publication Date Title
AU2013310924B2 (en) Method for producing antibody molecules having inter-species, intra-target cross-reactivity
US11629434B2 (en) Antibody screening methods
JP5791496B2 (ja) 推定成熟ｃｄｒのブラスティングならびにコホートライブラリの作製およびスクリーニングによる抗体の超ヒト化
Liu et al. Isolation of anti-toxin single domain antibodies from a semi-synthetic spiny dogfish shark display library
JP2025084951A (ja) 高解像度で広範なエピトープを網羅するために、ラクダ科動物抗体を生成する配列ベースのハイスループット法
JP2021072810A (ja) 可変ドメインｖｌおよびｖｈｈ誘導体に基づく高アフィニティおよび凝集耐性抗体
CN105111308A (zh) 抗N3pGlu淀粉样蛋白BETA肽抗体及其用途
CN107739405A (zh) 骆驼科动物来源的抗原结合多肽
CA2573259A1 (en) High affinity anti-tnf-alpha antibodies and method
US9090994B2 (en) Antibody humanization by framework assembly
WO2022037527A1 (zh) 结合bcma的单可变结构域及抗原结合分子
US20220073649A1 (en) Mixed binding domains
WO2022037528A1 (zh) 结合bcma的单可变结构域及抗原结合分子
CN103588876B (zh) 一种生产人源化抗体或抗原结合片段的方法
WO2025228315A1 (en) Anti-n3pglu amyloid beta antibodies and uses thereof
US20250092124A1 (en) Antibody molecule against growth and differentiation factor 15 and use thereof
HK40047350B (en) Antibody screening methods
HK40047350A (en) Antibody screening methods

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20190830